Invention Grant
- Patent Title: Anti-PD-L1 antibodies and uses thereof
-
Application No.: US15454939Application Date: 2017-03-09
-
Publication No.: US10759856B2Publication Date: 2020-09-01
- Inventor: Horacio G. Nastri , Christel Iffland , Olivier Leger , Qi An , Mark Cartwright , Sean D. McKenna , Vanita D. Sood , Gang Hao
- Applicant: Merck Patent GmbH
- Applicant Address: DE Darmstadt
- Assignee: Merck Patent GmbH
- Current Assignee: Merck Patent GmbH
- Current Assignee Address: DE Darmstadt
- Agency: Goodwin Procter LLP
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K45/06 ; A61K31/555 ; A61K39/395 ; A61K31/675 ; A61K31/7068 ; A61K31/282 ; A61K31/513 ; A61K31/519 ; A61K39/00
Abstract:
The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.
Public/Granted literature
- US20170253653A1 ANTI-PD-L1 ANTIBODIES AND USES THEREOF Public/Granted day:2017-09-07
Information query
